| Literature DB >> 15866756 |
Pavel Rossner1, Paolo Boffetta, Marcello Ceppi, Stefano Bonassi, Zdenek Smerhovsky, Karel Landa, Dagmar Juzova, Radim J Srám.
Abstract
There is evidence that increased frequency of chromosomal aberration (CA) in peripheral blood lymphocytes is a predictor of cancer, but further data are needed to better characterize CA as marker of cancer risk. From the archives of 15 laboratories we gathered cytogenetic records of 11,834 subjects who were free of cancer at the moment of blood drawing and who underwent cytogenetic examination for preventive purposes in the Czech Republic during 1975-2000. We linked these records to the national cancer registry, revealing a total of 485 cancer cases. Subjects were classified according to the percentiles of CA distribution within each laboratory as low (0-33rd percentile), medium (34-66th percentile), and high (66-100th percentile). Subjects were further classified by occupational exposure and by subclass of CA. We found a significant association between the overall cancer incidence and the presence of chromosome-type aberrations [relative risk (RR) for high vs. low CA level = 1.24; 95% confidence interval (CI), 1.03-1.50] but not chromatid-type aberrations. Stomach cancer showed a strong association with frequency of total CA (RR = 7.79; 95% CI, 1.01-60.0). The predictivity of CA observed in subjects exposed to various classes of carcinogens did not significantly differ from the group of nonexposed subjects. This study contributes to validation of CA as a predictive marker of cancer risk, in particular, of stomach cancer; the association between CA frequency and cancer risk might be limited to chromosome-type aberrations.Entities:
Mesh:
Year: 2005 PMID: 15866756 PMCID: PMC1257540 DOI: 10.1289/ehp.6925
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Distribution of subjects in the cohort by age at first test, sex, duration of follow-up, cancer frequency, and frequency of CAs.
| Median (25th–75th percentiles)
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Occupational exposure | No. of subjects | Mean age at first test (years) | Sex (% males) | Mean years since test | Cancer cases (%) | CAs | CTAs | CSAs |
| Ionizing radiation | 676 | 40.3 | 70.4 | 11.6 | 57 (8.4) | 2.5 (1.5–4.0) | 2.0 (1.0–3.0) | 1.0 (0.0–2.0) |
| Cytostatic drugs | 2,150 | 36.5 | 12.8 | 7.4 | 61 (2.8) | 2.0 (1.0–3.0) | 1.3 (1.0–2.0) | 0.0 (0.0–1.0) |
| Polyclic aromatic hydrocarbons | 2,241 | 39.4 | 86.1 | 10.1 | 108 (4.8) | 2.0 (1.0–3.5) | 1.5 (1.0–2.4) | 1.0 (0.0–1.0) |
| Aromatic amines | 851 | 40.3 | 57.8 | 9.0 | 28 (3.3) | 2.0 (1.3–3.0) | 1.8 (1.0–3.0) | 0.6 (0.0–1.0) |
| Other exposures | 4,031 | 38.0 | 58.7 | 10.7 | 170 (4.2) | 2.0 (1.0–3.0) | 1.0 (1.0–2.0) | 0.5 (0.0–1.0) |
| Nonexposed | 1,913 | 36.2 | 55.2 | 8.8 | 61 (3.2) | 2.0 (1.0–3.0) | 1.0 (0.5–2.0) | 0.0 (0.0–1.0) |
| Total cohort | 11,862 | 38.0 | 55.6 | 9.6 | 485 (4.1) | 2.0 (1.0–3.0) | 1.0 (1.0–2.0) | 0.5 (0.0–1.0) |
Results from the multivariate Cox regression analysis of CA frequency (total and by subclass) and cancer incidence.
| Incident cases (by tertile of CA distribution)
| Total CAs | RR≥1 (95% CI)
| ||||||
|---|---|---|---|---|---|---|---|---|
| Cancer site | ICD-9 code | Low | Medium | High | RRmedium (95% CI) | RRhigh (95% CI) | CTAS | CSAs |
| Lip, oral cavity, and pharynx | 140–149 | 4 | 1 | 9 | 0.23 (0.03–2.06) | 1.89 (0.55–6.50) | 1.61 (0.36–7.33) | 1.98 (0.61–6.42) |
| Digestive organs | 150–159 | 16 | 31 | 48 | 1.47 (0.80–2.70) | 1.86 (1.05–3.28) | 1.20 (0.69–2.09) | 1.46 (0.94–2.27) |
| Stomach | 151 | 1 | 3 | 12 | 2.25 (0.23–21.66) | 7.79 (1.01–60.03) | 1.43 (0.32–6.30) | 2.79 (0.79–9.83) |
| Colon, rectum | 153–154 | 13 | 24 | 22 | 1.41 (0.72–2.79) | 0.94 (0.47–1.89) | 1.12 (0.56–2.22) | 1.16 (0.68–1.99) |
| Respiratory and intrathoracic organs | 160–165 | 19 | 22 | 38 | 0.87 (0.47–1.61) | 1.02 (0.58–1.80) | 0.86 (0.49–1.50) | 1.26 (0.78–2.03) |
| Trachea, bronchus, and lung | 162 | 18 | 21 | 34 | 0.87 (0.46–1.64) | 0.96 (0.54–1.74) | 0.84 (0.48–1.50) | 1.27 (0.77–2.10) |
| Bone, connective tissue, skin, and breast | 170–175 | 31 | 51 | 46 | 1.29 (0.82–2.01) | 1.08 (0.68–1.73) | 1.19 (0.75–1.90) | 0.88 (0.62–1.26) |
| Skin (nonmelanoma) | 173 | 20 | 25 | 25 | 0.97 (0.54–1.75) | 0.89 (0.49–1.63) | 1.01 (0.56–1.83) | 0.81 (0.50–1.30) |
| Breast | 174 | 9 | 19 | 11 | 1.60 (0.72–3.55) | 0.97 (0.40–2.36) | 0.97 (0.44–2.13) | 1.05 (0.54–2.05) |
| Genitourinary organs | 179–189 | 33 | 45 | 40 | 1.05 (0.67–1.66) | 0.82 (0.51–1.32) | 0.93 (0.59–1.46) | 1.17 (0.80–1.71) |
| Uterus | 179–182 | 15 | 19 | 16 | 1.02 (0.52–2.01) | 0.94 (0.46–1.92) | 0.89 (0.45–1.74) | 1.32 (0.74–2.34) |
| Prostate | 185 | 3 | 2 | 7 | 0.49 (0.08–3.10) | 1.23 (0.29–5.28) | 0.81 (0.21–3.16) | 0.70 (0.20–2.41) |
| Bladder | 188 | 6 | 3 | 4 | 0.38 (0.09–1.53) | 0.34 (0.09–1.27) | 0.78 (0.21–2.88) | 0.70 (0.23–2.11) |
| Other and unspecified sites | 190–199 | 5 | 12 | 8 | 1.94 (0.68–5.54) | 1.17 (0.38–3.64) | 0.99 (0.37–2.68) | 3.91 (1.33–11.54) |
| Lymphatic and hematopoietic tissue | 200–208 | 5 | 11 | 10 | 1.70 (0.59–4.91) | 1.49 (0.50–4.44) | 0.66 (0.28–1.58) | 1.73 (0.75–4.04) |
| Total cancers | 140–208 | 113 | 173 | 199 | 1.17 (0.92–1.48) | 1.13 (0.89–1.43) | 1.02 (0.81–1.28) | 1.24 (1.03–1.50) |
Reference level: lowest tertile of CA distribution.
Reference level: subjects with “0” CTAs or CSAs.
p < 0.05.
Results from the multivariate Cox regression analysis of CA frequency (total and by subclass) and total cancer incidence by occupational exposure.
| Total CAs | RR≥1 (95% CI)
| ||||
|---|---|---|---|---|---|
| Occupational exposure | No. of subjects | RRmedium (95% CI) | RRhigh (95% CI) | CTAs | CSAs |
| Ionizing radiation | 676 | 1.42 (0.61–3.33) | 1.39 (0.61–3.16) | 1.35 (0.62–2.89) | 1.17 (0.65–2.10) |
| Cytostatic drugs | 2,150 | 1.09 (0.57–2.07) | 0.96 (0.50–1.85) | 0.95 (0.50–1.79) | 1.33 (0.79–2.25) |
| Polyclic aromatic hydrocarbons | 2,241 | 1.27 (0.73–2.25) | 1.39 (0.82–2.34) | 1.20 (0.70–2.04) | 1.56 (1.01–2.41) |
| Aromatic amines | 851 | 1.85 (0.59–5.80) | 1.29 (0.41–4.07) | 1.06 (0.31–3.61) | 0.84 (0.40–1.78) |
| Other exposures | 4,031 | 1.04 (0.71–1.53) | 0.86 (0.58–1.26) | 0.83 (0.57–1.29) | 1.17 (0.85–1.61) |
| Nonexposed | 1,913 | 1.23 (0.68–2.22) | 1.55 (0.80–3.01) | 1.13 (0.63–2.03) | 1.33 (0.80–2.21) |
| Total | 11,862 | 1.17 (0.92–1.48) | 1.13 (0.88–1.43) | 1.02 (0.81–1.28) | 1.24 (1.03–1.50)[ |
Reference level: lowest tertile of CA distribution.
Reference level: subjects with “0” CTAs or CSAs.
p < 0.05.